FIRST WAVE BIOPHARMA (FWBI) Fundamental Analysis & Valuation

NASDAQ:FWBI • US33749P4081

Current stock price

2.96 USD
+0.13 (+4.59%)
Last:

This FWBI fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. FWBI Profitability Analysis

1.1 Basic Checks

  • FWBI had negative earnings in the past year.
  • In the past year FWBI has reported a negative cash flow from operations.
  • FWBI had negative earnings in each of the past 5 years.
  • In the past 5 years FWBI always reported negative operating cash flow.
FWBI Yearly Net Income VS EBIT VS OCF VS FCFFWBI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 -20M -40M -60M -80M

1.2 Ratios

  • FWBI's Return On Assets of -233.87% is on the low side compared to the rest of the industry. FWBI is outperformed by 92.62% of its industry peers.
  • FWBI's Return On Equity of -446.80% is on the low side compared to the rest of the industry. FWBI is outperformed by 78.56% of its industry peers.
Industry RankSector Rank
ROA -233.87%
ROE -446.8%
ROIC N/A
ROA(3y)-408.67%
ROA(5y)-343.91%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
FWBI Yearly ROA, ROE, ROICFWBI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 0 -10K -20K -30K

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for FWBI so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
FWBI Yearly Profit, Operating, Gross MarginsFWBI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. FWBI Health Analysis

2.1 Basic Checks

  • The number of shares outstanding for FWBI has been increased compared to 1 year ago.
  • Compared to 1 year ago, FWBI has an improved debt to assets ratio.
FWBI Yearly Shares OutstandingFWBI Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 500K 1M 1.5M
FWBI Yearly Total Debt VS Total AssetsFWBI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M 10M

2.2 Solvency

  • FWBI has an Altman-Z score of -43.89. This is a bad value and indicates that FWBI is not financially healthy and even has some risk of bankruptcy.
  • FWBI has a Altman-Z score of -43.89. This is amonst the worse of the industry: FWBI underperforms 94.34% of its industry peers.
  • FWBI has a Debt/Equity ratio of 0.17. This is a healthy value indicating a solid balance between debt and equity.
  • FWBI has a Debt to Equity ratio of 0.17. This is in the lower half of the industry: FWBI underperforms 66.72% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.17
Debt/FCF N/A
Altman-Z -43.89
ROIC/WACCN/A
WACCN/A
FWBI Yearly LT Debt VS Equity VS FCFFWBI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 -10M -20M -30M

2.3 Liquidity

  • A Current Ratio of 1.58 indicates that FWBI should not have too much problems paying its short term obligations.
  • FWBI's Current ratio of 1.58 is on the low side compared to the rest of the industry. FWBI is outperformed by 81.13% of its industry peers.
  • A Quick Ratio of 1.58 indicates that FWBI should not have too much problems paying its short term obligations.
  • FWBI has a worse Quick ratio (1.58) than 79.59% of its industry peers.
Industry RankSector Rank
Current Ratio 1.58
Quick Ratio 1.58
FWBI Yearly Current Assets VS Current LiabilitesFWBI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 5M 10M 15M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. FWBI Growth Analysis

3.1 Past

  • FWBI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 75.50%, which is quite impressive.
EPS 1Y (TTM)75.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%97.18%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • FWBI is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 14.93% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y95.87%
EPS Next 2Y40.79%
EPS Next 3Y25.45%
EPS Next 5Y14.93%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
FWBI Yearly Revenue VS EstimatesFWBI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 100M 200M 300M
FWBI Yearly EPS VS EstimatesFWBI Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -10K -20K -30K

More info and screens

Find the best growth stocksShow best growing peers

1

4. FWBI Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for FWBI. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for FWBI. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
FWBI Price Earnings VS Forward Price EarningsFWBI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
FWBI Per share dataFWBI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -20 -40 -60 -80

4.3 Compensation for Growth

  • A more expensive valuation may be justified as FWBI's earnings are expected to grow with 25.45% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.79%
EPS Next 3Y25.45%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. FWBI Dividend Analysis

5.1 Amount

  • No dividends for FWBI!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

FWBI Fundamentals: All Metrics, Ratios and Statistics

FIRST WAVE BIOPHARMA

NASDAQ:FWBI (5/16/2024, 8:00:00 PM)

2.96

+0.13 (+4.59%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-12
Earnings (Next)08-14
Inst Owners5.98%
Inst Owner ChangeN/A
Ins Owners10.98%
Ins Owner Change0%
Market Cap4.62M
Revenue(TTM)N/A
Net Income(TTM)-16.10M
Analysts80
Price Target36.72 (1140.54%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-1.66%
Min EPS beat(2)-29.99%
Max EPS beat(2)26.67%
EPS beat(4)2
Avg EPS beat(4)-16.31%
Min EPS beat(4)-78.17%
Max EPS beat(4)26.67%
EPS beat(8)4
Avg EPS beat(8)-7.61%
EPS beat(12)4
Avg EPS beat(12)-48.37%
EPS beat(16)4
Avg EPS beat(16)-53.16%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-10%
EPS NQ rev (1m)-0.62%
EPS NQ rev (3m)-6.81%
EPS NY rev (1m)0%
EPS NY rev (3m)32.61%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.28
P/tB 2.41
EV/EBITDA N/A
EPS(TTM)-88.75
EYN/A
EPS(NY)-3.67
Fwd EYN/A
FCF(TTM)-7.93
FCFYN/A
OCF(TTM)-7.93
OCFYN/A
SpS0
BVpS2.31
TBVpS1.23
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -233.87%
ROE -446.8%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-408.67%
ROA(5y)-343.91%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.17
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.58
Quick Ratio 1.58
Altman-Z -43.89
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)75.5%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%97.18%
EPS Next Y95.87%
EPS Next 2Y40.79%
EPS Next 3Y25.45%
EPS Next 5Y14.93%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-24.32%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y44.59%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y44.59%
OCF growth 3YN/A
OCF growth 5YN/A

FIRST WAVE BIOPHARMA / FWBI Fundamental Analysis FAQ

What is the ChartMill fundamental rating of FIRST WAVE BIOPHARMA (FWBI) stock?

ChartMill assigns a fundamental rating of 1 / 10 to FWBI.


Can you provide the valuation status for FIRST WAVE BIOPHARMA?

ChartMill assigns a valuation rating of 1 / 10 to FIRST WAVE BIOPHARMA (FWBI). This can be considered as Overvalued.


What is the profitability of FWBI stock?

FIRST WAVE BIOPHARMA (FWBI) has a profitability rating of 0 / 10.


What is the expected EPS growth for FIRST WAVE BIOPHARMA (FWBI) stock?

The Earnings per Share (EPS) of FIRST WAVE BIOPHARMA (FWBI) is expected to grow by 95.87% in the next year.